Toward a Predictive Model for a Cell



OPINION | Last month, a really nice piece of systems biology work was published in the journal Cell in which researchers developed a predictive model for a free cell, in this case the Archea organism, Halobacterium salinarum NRC-1.What's more, the authors suggest that even though their model is for a relatively simply organism (~2400 genes), the approach used to build it can probably be used to tackle complex organisms.

The authors of the paper, Environmental and Gene Regulatory Influence Network (EGRIN): A Predictive Model for Transcriptional Control of Physiology in a Free Living Cell, say they used a data-driven discovery approach to determine regulatory and functional interrelationships among roughly 80 percent of NRC-1's genes.

"Using relative changes in 72 transcription factors and 9 environmental factors (EFs) this model accurately predicts dynamic transcriptional responses of all these genes in 147 newly collected experiments representing completely novel genetic backgrounds and environments - suggesting a remarkable degree of network completeness. Using this model we have constructed and tested hypotheses critical to this organism's interaction with its changing hypersaline environment. This study supports the claim that the high degree of connectivity within biological and EF networks will enable the construction of similar models for any organism from relatively modest numbers of experiments."

It is perhaps unsurprising that much of the work was done at the Institute for Systems Biology (ISB) and led by current ISB researcher Nitin Baliga and a former ISB researcher now at the Center for Comparative Functional Genomics, New York University: Richard Bonneau.

Indeed, this was a classic systems biology exercise, as espoused by ISB president and founder Lee Hood (see What Is Systems Biology?), who was among the report's authors. The work involved global measurements (genome-wide); quantitative and dynamic measurements; careful system perturbation (genetic and environmental); integrating different data types; and of course adherence to the systems biology cycle of perturbation-measurement-model-hypothesis-perturbation.

There were several hurdles. For example, roughly 38 percent of NRC-1's genes had little or no functional assignments. The group incorporated functional relationships from comparative genomics as well as predicted structural and domain similarities until achieving "nearly 90 percent...meaningful association with either a characterized protein, a protein family or a structural fold." Similar techniques were used to boost the number of putative transcription factors.

Two hundred sixty-six microarray experiments were used to construct the networks, and 147 microarray experiments were used to validate model predictions. Network construction was based the "Inferelator algorithm" (catchy name) developed in large measure by Bonneau. The authors note the number of experiments required was relatively modest, given EGRIN's model's high accuracy, and suggest the interdependence of many networks and, at least for metabolism, that cells may usually function in one or a few dominant states.

"What is powerful about this approach is that it took under six years to move from genome sequence to this level of understanding for a relatively poorly-studied organism. Indeed, it would be significantly quicker to implement the same approach with a newly sequenced organism given that much of the scientific methods including experimental procedures, algorithms, and software have been delineated through our study," write the authors.

Of course, there's still work to be done on EGRIN. Many other regulatory mechanisms - small RNAs, epigenetic modifications, post-translational modifications, metabolite-based feedback - are not included and may account, at least in part, for its failure to predict what 20 percent of the genes are doing.
-----------------------
This article first appeared in Bio-IT World's Systems Biology newsletter.  Click here for a free subscription to Systems Biology.

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .